BioInformant - Stem Cell Industry News

The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based - An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD | BioInformant In the rapidly evolving field of cell therapy, scalability and accessibility remain two of the biggest challenges for widespread patient impact. Cellistic, a leading company that is pioneering allogen...

The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based – An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD - bioinformant.com/cellistic-st...

RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01 | BioInformant FREDERICK, Md. and PLANO, Texas, Oct. 6, 2025 — RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Se...

RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01 - bioinformant.com/roosterbio-a...

BBG Advanced Therapies collects first cell donation on one-of-a-kind bus | BioInformant New vehicle to help enable lifesaving new advanced therapies The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global ...

BBG Advanced Therapies collects first cell donation on one-of-a-kind bus - bioinformant.com/bbg-advanced...

The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global healthcare.

Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering | BioInformant Across 2025, a striking trend has emerged in biotechnology. Major pharmaceutical companies are racing to acquire in vivo cell engineering platforms, signaling that reprogramming cells inside the body ...

Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering - bioinformant.com/big-pharma-c...

CIRM’s iPSC Repository Closes, Marking the End of a Landmark Resource for Stem Cell Research | BioInformant Sadly, in July 2025, the California Institute for Regenerative Medicine (CIRM) officially closed its iPSC Repository, marking the end of one of the world’s most comprehensive publicly funded collectio...

CIRM’s iPSC Repository Closes, Marking the End of a Landmark Resource for Stem Cell Research - bioinformant.com/cirms-ipsc-r...
@cirmnews.bsky.social

Legendary NFL Quarterback Bernie Kosar Launches X Pro. Athlete Cognitive Longevity Wellness Program to Push the Limits of Brain Performance with Crowley Center for Regenerative Biotherapeutics in coll... Backed by a $10M Age Zero™ Regenerelle® in-kind contribution by the Crowley Family,  Team Bernie™ brings together NFL veterans and longevity innovators to explore next-generation cognitive optimizatio...

NFL legend Bernie Kosar launches the X Pro Athlete Cognitive Longevity Program with the Crowley Center and Regenerelle® to push the limits of brain performance

bioinformant.com/bernie-kosar...

Qihan Biotech’s QN-139b becomes First iPSC-derived CAR NK therapy for Autoimmune Disease | BioInformant A new chapter is beginning for iPSCs: Qihan Biotech, a leading innovator in cell engineering, has reported the first clinical use of an induced pluripotent stem cell (iPSC)-derived CAR natural killer ...

Qihan Biotech’s QN-139b becomes First iPSC-derived CAR NK therapy for Autoimmune Disease - bioinformant.com/qihan-biotec...

Induced Pluripotent Stem Cell (iPSC) Industry Trends for 2025 Induced pluripotent stem cells (iPS cells or iPSCs) are laboratory-made pluripotent stem cells that are produced using non-controversial adult cells. They are derived from somatic cells through reprog...

Induced Pluripotent Stem Cell (iPSC) Industry Trends Dominating in 2025 - bioinformant.com/ipsc-industr...

@riken-brc-jp.bsky.social @reprocell.bsky.social @evotec.bsky.social @thermofishersci.bsky.social

Novo Withdraws from $598M Heartseed Partnership; Pursues Short-Term Profit Over iPSC Potential | BioInformant Sadly, Novo Nordisk has ended its $598 million collaboration with Tokyo-based biotech Heartseed, marking a major shift in its approach to regenerative medicine and iPSCs, specifically.  The partnershi...

Novo Withdraws from $598M Heartseed Partnership; Pursues Short-Term Profit Over iPSC Potential - bioinformant.com/novo-withdra...
@novonordisk.bsky.social

TriHaz Solutions Opens New Nashville, Tennessee Facility to Expand Regulated Medical Waste Services Across Tennessee | BioInformant Nashville, TN – July 16, 2025 – TriHaz Solutions, a trusted provider of regulated medical waste management, is proud to announce the opening of a new operational facility in Nashville, Tennesee. This ...

TriHaz Solutions Opens New Nashville, Tennessee Facility to Expand Regulated Medical Waste Services Across Tennessee - bioinformant.com/trihaz-solut...

uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells | BioInformant GERMANTOWN, MD, September 17, 2025 – uBriGene Biosciences, a leader in CGT CDMO and iPSC manufacturing technology development, announced the launch of its 2nd-Generation iPSC Reprogramming Kit, powere...

uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells - bioinformant.com/ubrigene-ips...

TEDCO Announces Panel to Discuss the Road to Clinical Trials at 2025 Entrepreneur Expo | BioInformant COLUMBIA, Md., October 9, 2025 — TEDCO, Maryland’s economic engine for technology companies, announces the panel “The Road to Clinical Trials” to take place at the upcoming  2025 Entrepreneur Expo at ...

TEDCO Announces Panel to Discuss Road to Clinical Trials at 2025 Entrepreneur Expo - bioinformant.com/tedco-panel-...

TEDCO, MD's economic engine for technology companies, announces the panel “The Road to Clinical Trials” to take place at the upcoming 2025 Entrepreneur Expo.

Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study | BioInformant The final analysis including the 24-month evaluation of Xintela’s (XINT) clinical study on XSTEM for knee osteoarthritis has now been completed. The results show continued safety, reduction of knee pa...

Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study - bioinformant.com/xintelas-xst...

Kexing Biopharm's Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF | BioInformant SHENZHEN, China, Sept. 16, 2025 — Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Master File (...

Kexing Biopharm’s Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF - bioinformant.com/kexing-bioph...

Maryland Governor Wes Moore to Speak at TEDCO's 2025 Entrepreneur Expo | BioInformant Join us in College Park on October 21 during the lunch keynote session COLUMBIA, Md., Sept. 29, 2025 — TEDCO, Maryland’s economic engine for technology companies, announces the attendance of Maryland ...

Maryland Governor Wes Moore to Speak at TEDCO’s 2025 Entrepreneur Expo - bioinformant.com/maryland-gov...

TEDCO, Maryland’s economic engine for technology companies, announces the attendance of Maryland Governor Wes Moore at the upcoming 2025 Entrepreneur Expo on Oct 21, 2025.

Qkine launches cell therapy grade recombinant proteins to support next-generation therapies | BioInformant 1st October 2025, Cambridge, UK – Qkine, Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, today announced the launch of its Cell The...

Qkine launches cell therapy grade recombinant proteins to support next-generation therapies - bioinformant.com/qkine/
@qkine.bsky.social

HeartBeat.bio and Boehringer Ingelheim Use Human iPSC-Based Cardioids to Model Inherited Cardiomyopathies | BioInformant HeartBeat.bio Joins Forces with Boehringer Ingelheim to Advance Gene Therapies for Inherited Heart Muscle Disorders Vienna, Austria – September 23, 2025 – HeartBeat.bio has entered into a research col...

Heartbeat.bio and Boehringer Ingelheim Use Human iPSC-Based Cardioids to Model Inherited Cardiomyopathies - bioinformant.com/heartbeat-bi...

Clinical #StemCell Services: REPROCELL's experts in cell therapy manufacturing will take you through all the stages of your regenerative medicine project

www.reprocell.com/clinical-ste...

CytoMed Expands NK cells from Stored Cord Blood, Creates to New Cord Blood-Derived Biotech Under LongevityBank | BioInformant CytoMed Therapeutics Seeks to Advance Cord Blood-Derived Therapies For Auto-immune Diseases and Cancers Long-term intention is to spin off LongevityBank as standalone biotech, offering immune cell ban...

CytoMed Expands NK cells from Stored Cord Blood, Creates to New Cord Blood-Derived Biotech Under LongevityBank - bioinformant.com/cytomed-ther...

@cytomedtech.bsky.social

Mytos Advances Automated iPSC Manufacturing through Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip | BioInformant Mytos Announces Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip to Power Next-Generation Cell Therapy Trials Mytos’ iDEM platform replaces traditional iPSC manufacturing with a ...

Mytos Advances Automated iPSC Manufacturing through Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip - bioinformant.com/mytos-announ...

European Commission Grants First Approval for Expanded Cord Blood Stem Cell Therapy (Zemcelpro®) | BioInformant September 10, 2025 — In a landmark move for regenerative medicine, the European Commission has conditionally authorized Zemcelpro®, the first treatment in Europe to use expanded umbilical cord blood s...

European Commission Grants First Approval for Expanded Cord Blood Stem Cell Therapy (Zemcelpro®) - bioinformant.com/european-com...

Takara Bio Europe launches Cellartis® MSC EV Wonder™, a defined, xeno-free medium for high-yield EV production | BioInformant September 24, 2025 – Takara Bio Europe announces the launch of Cellartis® MSC EV Wonder™, a defined, xeno-free medium engineered for the scalable production of extracellular vesicles (EVs) from human ...

Takara Bio Europe launches Cellartis® MSC EV Wonder™, a defined, xeno-free medium for high-yield EV production - bioinformant.com/takara-bio-e...

Ncardia Launches First-of-Its-Kind iPSC-Derived Non-Human Primate Cardiomyocytes to Advance Cardiac Safety Research | BioInformant LEIDEN, Netherlands — Ncardia, a leader in stem cell–based solutions for drug discovery and safety assessment, today announced the launch of Ncyte® NHP-C vCardiomyocytes, the first commercially availa...

Ncardia Launches First-of-Its-Kind iPSC-Derived Non-Human Primate Cardiomyocytes to Advance Cardiac Safety Research - bioinformant.com/ncardia-ipsc...

Congress Moves to Reauthorize Funding for National Cord Blood and Bone Marrow Transplant Programs | BioInformant Legislation would authorize $280 million over 5 years to support National Cord Blood and Bone Marrow Transplant Programs. A bipartisan group of lawmakers in the U.S. House has introduced new legislati...

Congress Moves to Reauthorize Funding for National Cord Blood and Bone Marrow Transplant Programs - bioinformant.com/fundering-co...

Precision Over Hype: Biogenomics’ Genovia Sets a New Standard in Exosome-Based Regenerative Aesthetics | BioInformant Los Angeles, CA – September 4, 2025 – As industry scrutiny intensifies over cosmetic products making bold but unverified “exosome” claims, Biogenomics, a biotech company advancing regenerative aesthet...

Precision Over Hype: Biogenomics’ Genovia Sets a New Standard in #Exosome-Based Regenerative Aesthetics - bioinformant.com/precision-ov...

Sanatela AT Medical Solutions Inc. Announces Groundbreaking Patent Issuance for Cancer Stem Cell Identification and Precision Treatment Platform | BioInformant Rochester, NY, September 24, 2025 – After two decades of pioneering hematology and cancer stem cell research, Sanatela AT Medical Solutions Inc. proudly announces that the United States Patent and Tra...

Sanatela AT Medical Solutions Inc. Announces Groundbreaking Patent Issuance for Cancer Stem Cell Identification and Precision Treatment Platform - bioinformant.com/sanatela-at-...

Shineco Establishes Biological Cell Digital Division to Integrate iPSC Technology Assets with Blockchain Technology | BioInformant BEIJING, Aug. 13, 2025 — Shineco Inc. (NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, announced the establishment of a Biological Cell Digital Business Div...

Shineco Establishes Biological Cell Digital Division to Integrate iPSC Technology Assets with Blockchain Technology - bioinformant.com/shineco-biol...

AABB’s Cell and Gene Therapy Standards for Pharmacy, First Edition, Takes Effect October 1 | BioInformant Sept 8, 2025, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce the release of the first edition of Cell and Gene Therapy Standards for Pharmacy,...

AABB’s Cell and Gene Therapy Standards for Pharmacy, First Edition, Takes Effect October 1 - bioinformant.com/aabbs-cell-a...
@aabbupdates.bsky.social

Cord Blood Industry Consolidation Escalates in 2025 | BioInformant The cord blood industry had strong growth during the early 2000's. However, the market has matured and consolidated over the past 10 years.

Cord Blood Industry Consolidation Escalates in 2025 - bioinformant.com/cord-blood-i...

EU Grants Approval to Zemcelpro, a Cord Blood–Derived Stem Cell Therapy for Blood Cancer Patients | BioInformant In August 2025, the European Commission (EC) granted conditional marketing authorization (CMA) to Cordex Biologics, a subsidiary of ExCellThera, for Zemcelpro® (UM171 Cell Therapy), a personalized ste...

EU Grants Approval to Zemcelpro, a Cord Blood–Derived Stem Cell Therapy for Blood Cancer Patients - bioinformant.com/eu-grants-ap...